Follicular lymphoma treatment patterns between 2000 and 2014: a SEER-Medicare analysis of elderly patients
| Autor: | Karen Keating, Madhuram Nagarajan, Eberechukwu Onukwugha, Aakash Bipin Gandhi, Jean Yared, Sreevalsa Appukkuttan, Husam Albarmawi |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Oncology
Male Cancer Research medicine.medical_specialty Vincristine Cyclophosphamide Follicular lymphoma Comorbidity Medicare History 21st Century 03 medical and health sciences 0302 clinical medicine Internal medicine Epidemiology medicine Humans Doxorubicin Lymphoma Follicular Aged Aged 80 and over business.industry Age Factors Disease Management General Medicine medicine.disease Combined Modality Therapy United States Non-Hodgkin's lymphoma Treatment Outcome 030220 oncology & carcinogenesis Prednisolone Rituximab Female business 030215 immunology medicine.drug SEER Program |
| Zdroj: | Future oncology (London, England). 16(8) |
| ISSN: | 1744-8301 |
| Popis: | Aim: Characterize follicular lymphoma (FL) treatment patterns among elderly patients using a dataset with longer follow-up time. Materials & methods: Using the linked Surveillance, Epidemiology and End Results-Medicare data, we identified patients diagnosed with FL between 2000 and 2013 with claims data until 2014. We investigated the treatments received and assigned them to lines of treatment. Results: We identified 10,238 elderly patients. Over a 4.7-year median follow-up, 78% of the patients received at least first-line treatment. Fewer individuals received second-line (47%) and third-line (30%) treatments. RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone), RCVP (rituximab, cyclophosphamide, vincristine and prednisolone) and rituximab monotherapy were the most common treatment regimens. Conclusion: One in five elderly patients did not receive FL-directed therapy. The most common treatment regimens were limited to RCHOP, RCVP and rituximab monotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|